Background Image
Previous Page  164 / 182 Next Page
Show Menu
Previous Page 164 / 182 Next Page
Page Background





Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, Shilli-

day BB, DeWalt DA, Pignone MP. Predictors of opioid missues in patients with chronic

pain: a prospective cohort study. BMC Health Services Research 2006; 6: 46.


Jacobsen R, Moldrup C, Christrup L. Clinical rationale for administering fentanyl to can-

cer pain patients: two Delphi surveys of pain management experts in Denmark. J Opioid

Manag 2008; 4 (6): 383-391.


Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics

of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid

Manage 2010; 6: 17-26.


Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous

morphine in the management of cancer pain: a double-blind cross-over study. Pain

1996; 67: 443-449.


Kanpolat Y, Savas A, Ucar T, Torun F. CT-guided percutaneous selective cordotomy for

treatment of intractable pain in patients with malignant pleural mesothelioma. Acta

Neurochirurgica 2002; 144: 595-599.


Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Ci-

cero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD. Foundations of opioid

risk management. Clinical Journal of Pain 2007; 23: 103-118.


Keating HJ, Kundrat M. Patient-controlled analgesia with nitrous oxide in cancer pain.

Journal of Pain and Symptom Management 1996; 11(2): 126-130.


Klepstad P, Kaasa S, Borchgrevink PC. Starting step III opioids for moderate to severe

pain in cancer patients: dose titration: a systematic review. Palliat Med 2011; 25(5):



Krainick JU, Thoden U. Experience with dorsal column stimulation (DSC) in the opera-

tive treatment of chronic intractable pain. Journal of Neurosurgical Sciences 1974; 18:



Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability

of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with

cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, cross-

over trial with a 10-month, open-label extension treatment period. Clin Ther 2009;

31(6): 1177-1191.


Laverty D. Actiq: an effective oral treatment for cancer related breakthrough pain. Br J

Community Nurs 2007; 12(7): 311.


Laverty D. Treating cancer-related breakthrough pain: the oral transmucosal route. Int J

Palliat Nurs 2007; 13(7): 326-331.


Laverty DM Davies A. Assessment. In: Davies AN (Hrsg.), Cancer-related breakthrough

pain. Oxford: Oxford University Press; 2006. p. 23-30.


Lawrie I, Lloyd-Williams M, Waterhouse E. Breakthrough strong opioid analgesia

prescription in patients using transderaml fentanyl admitted to a hospice. American

Journal of Hospice and Palliative Care 2003; 20: 229-230.